In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
The Rogers Foundation announces a second landmark gift, building on its $130 million gift in 2014, to sustain the Ted Rogers Centre for Heart Research in perpetuity and bring the promise of precision cardiac health to patients across Canada and globally. In 2014, the...
Please join us for an ECHO webinar on Tuesday May 25, 2021 (11 am – 12 pm) featuring Dr. Misti Ushio (CEO, TARA Biosystems). Dr. Ushio’s presentation entitled, “TARA Biosystems: our journey of engineering human biology to transform cardiac drug discovery”, will feature an overview of TARA Biosystems, its technologies and the story behind its success.
TARA Biosystems harnesses innovations in stem cell biology and tissue engineering to generate in vitro biology that recapitulates human physiology with unprecedented fidelity. Their platform captures integrated physiologic endpoints of human cardiac function across a wide repertoire of cardiac disease phenotypes. Their data facilitates decisive evaluation of the efficacy and risk of novel medicines, increasing the probability of success and decreasing the long timeframes typically associated with drug discovery efforts.
Register in advance for this meeting: https://us02web.zoom.us/meeting/register/tZ0scO-pqT8oEtBOllvBH-I5YK87lqTB1fd8
After registering, you will receive a confirmation email containing information about joining the webinar.
ECHO is an entrepreneurship training program, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP), the University of Toronto component of the Ted Rogers Centre for Heart Research, and (ii) the Health Innovation Hub (H2i).
